| Literature DB >> 29483653 |
Daniel Kotlarz1, Benjamin Marquardt1, Tuva Barøy2,3, Way S Lee4, Liza Konnikova5,6,7, Sebastian Hollizeck1, Thomas Magg1, Anna S Lehle1, Christoph Walz8, Ingo Borggraefe1, Fabian Hauck1, Philip Bufler1, Raffaele Conca1, Sarah M Wall5, Eva M Schumacher9, Doriana Misceo2,3, Eirik Frengen2,3, Beint S Bentsen9,10, Holm H Uhlig11, Karl-Peter Hopfner12, Aleixo M Muise13,14,15, Scott B Snapper5,6,16, Petter Strømme3,9, Christoph Klein17.
Abstract
Transforming growth factor (TGF)-β1 (encoded by TGFB1) is the prototypic member of the TGF-β family of 33 proteins that orchestrate embryogenesis, development and tissue homeostasis1,2. Following its discovery 3 , enormous interest and numerous controversies have emerged about the role of TGF-β in coordinating the balance of pro- and anti-oncogenic properties4,5, pro- and anti-inflammatory effects 6 , or pro- and anti-fibrinogenic characteristics 7 . Here we describe three individuals from two pedigrees with biallelic loss-of-function mutations in the TGFB1 gene who presented with severe infantile inflammatory bowel disease (IBD) and central nervous system (CNS) disease associated with epilepsy, brain atrophy and posterior leukoencephalopathy. The proteins encoded by the mutated TGFB1 alleles were characterized by impaired secretion, function or stability of the TGF-β1-LAP complex, which is suggestive of perturbed bioavailability of TGF-β1. Our study shows that TGF-β1 has a critical and nonredundant role in the development and homeostasis of intestinal immunity and the CNS in humans.Entities:
Mesh:
Substances:
Year: 2018 PMID: 29483653 PMCID: PMC6309869 DOI: 10.1038/s41588-018-0063-6
Source DB: PubMed Journal: Nat Genet ISSN: 1061-4036 Impact factor: 38.330